Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Brendan Melck is an analyst in the IHS Life Sciences practice.
Life Sciences Polish pharma associations unite in appeal for greater access to biologics 18 December 2019 Brendan Melck Poland's pricing and...
Life Sciences Germany’s fixed pricing for medicines faces European reckoning 04 November 2019 Brendan Melck Fixed prices for prescription medicines...
Life Sciences New payment-by-results and payback regulations for Bulgaria 17 May 2019 Brendan Melck Earlier this year, important amendments...
Life Sciences Medical supplies to Czech hospitals to be stopped after call to reveal drug prices in tenders 17 October 2018 Brendan Melck The...
Life Sciences Drug supply shortages in Germany 17 May 2018 Brendan Melck Drug supply shortages have become an increasingly pressing issue in...
Life Sciences Lithuania's drug cost-containment initiatives – getting tough on pricing 12 September 2017 Brendan Melck Following several years...
Life Sciences Austria: Hastily implemented legal changes hit pharma industry 03 May 2017 Brendan Melck A legal amendment implemented pushed...
Life Sciences Changes to AMNOG in the Pharmaceutical Care Strengthening Act 06 September 2016 Brendan Melck The Pharma Dialogue - a process...
Life Sciences Greek pharma industry unites against growing burden of clawback 10 June 2016 Brendan Melck In a show of solidarity for the pharmaceutical...
Life Sciences OTC in CEE: A way out of the regulatory jungle 21 December 2015 Brendan Melck Central and Eastern Europe (CEE) is often seen as...
